Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-/][1,2,4]triazine p38α Mitogen-Activated Protein Kinase InhibitorsHYNES, John; DYCKMAN, Alaric J; PITT, Sidney et al.Journal of medicinal chemistry (Print). 2008, Vol 51, Num 1, pp 4-16, issn 0022-2623, 13 p.Article

5-Amino-pyrazoles as potent and selective p38α inhibitorsDAS, Jagabandhu; MOQUIN, Robert V; NEWITT, John A et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 23, pp 6886-6889, issn 0960-894X, 4 p.Article

Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitorsKYOUNG SOON KIM; SONGFENG LU; WILLIAMS, David K et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 15, pp 3937-3942, issn 0960-894X, 6 p.Article

Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitorsSHUQUN LIN; WROBLESKI, Stephen T; KIEFER, Susan E et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 19, pp 5864-5868, issn 0960-894X, 5 p.Article

Inhibitors of human mitotic kinesin Eg5 : Characterization of the 4-phenyl-tetrahydroisoquinoline lead seriesTARBY, Christine M; KALTENBACH, Robert F; FAIRCHILD, Craig R et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 8, pp 2095-2100, issn 0960-894X, 6 p.Article

The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutantsTOKARSKI, John S; NEWITT, John A; DIANLIN XIE et al.Cancer research (Baltimore). 2006, Vol 66, Num 11, pp 5790-5797, issn 0008-5472, 8 p.Article